Details for New Drug Application (NDA): 208589
✉ Email this page to a colleague
NDA 208589 describes CLOBETASOL PROPIONATE, which is a drug marketed by Alembic, Glenmark Pharms Ltd, Novast Labs, Padagis Israel, Taro, Amneal, Aurobindo Pharma Usa, Chartwell Rx, Cosette, Encube, Fougera Pharms Inc, Glenmark Speclt, Lupin Ltd, Pai Holdings Pharm, Rising, Teva Pharms Usa, Torrent, Xiromed, Zydus Pharms, Fougera Pharms, Padagis Us, Actavis Mid Atlantic, Epic Pharma Llc, Zydus Lifesciences, Macleods Pharms Ltd, Novel Labs Inc, Hikma, Prinston Inc, Quagen, Saptalis Pharms, Wockhardt Bio Ag, Apotex, Sciegen Pharms Inc, Eyenovia, and Ani Pharms, and is included in eighty-one NDAs. It is available from thirty-seven suppliers. There are two patents protecting this drug. Additional details are available on the CLOBETASOL PROPIONATE profile page.
The generic ingredient in CLOBETASOL PROPIONATE is clobetasol propionate. There are fourteen drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.
The generic ingredient in CLOBETASOL PROPIONATE is clobetasol propionate. There are fourteen drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.
Summary for 208589
| Tradename: | CLOBETASOL PROPIONATE |
| Applicant: | Pai Holdings Pharm |
| Ingredient: | clobetasol propionate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 208589
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | OINTMENT;TOPICAL | Strength | 0.05% | ||||
| Approval Date: | Jan 23, 2019 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
